Connexin43 recruits PTEN and Csk to inhibit c-Src activity in glioma cells and astrocytes by González-Sánchez, Ana et al.
Oncotarget49819www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 31
Connexin43 recruits PTEN and Csk to inhibit c-Src activity in 
glioma cells and astrocytes
Ana González-Sánchez1, Myriam Jaraíz-Rodríguez1, Marta Domínguez-Prieto1, 
Sandra Herrero-González1, José M. Medina1, Arantxa Tabernero1
1Instituto de Neurociencias de Castilla y León (INCYL), Departamento de Bioquímica y Biología Molecular, Universidad de 
Salamanca, Salamanca, Spain
Correspondence to: Arantxa Tabernero, email: ataber@usal.es
Keywords: connexin, Src, glia, CNS, gap junctions
Received: December 10, 2015    Accepted: June 26, 2016    Published: July 06, 2016
AbstrAct
Connexin43 (Cx43), the major protein forming gap junctions in astrocytes, 
is reduced in high-grade gliomas, where its ectopic expression exerts important 
effects, including the inhibition of the proto-oncogene tyrosine-protein kinase Src 
(c-Src). In this work we aimed to investigate the mechanism responsible for this 
effect. The inhibition of c-Src requires phosphorylation at tyrosine 527 mediated 
by C-terminal Src kinase (Csk) and dephosphorylation at tyrosine 416 mediated by 
phosphatases, such as phosphatase and tensin homolog (PTEN). Our results showed 
that the antiproliferative effect of Cx43 is reduced when Csk and PTEN are silenced 
in glioma cells, suggesting the involvement of both enzymes. Confocal microscopy 
and immunoprecipitation assays confirmed that Cx43, in addition to c-Src, binds to 
PTEN and Csk in glioma cells transfected with Cx43 and in astrocytes. Pull-down 
assays showed that region 266–283 in Cx43 is sufficient to recruit c-Src, PTEN and 
Csk and to inhibit the oncogenic activity of c-Src. As a result of c-Src inhibition, PTEN 
was increased with subsequent inactivation of Akt and reduction of proliferation of 
human glioblastoma stem cells. We conclude that the recruitment of Csk and PTEN 
to the region between residues 266 and 283 within the C-terminus of Cx43 leads to 
c-Src inhibition.
INtrODUctION
Connexin43 (Cx43) is an integral membrane 
protein that assembles to form gap junction channels and 
hemichannels in different cell types, including astrocytes, 
where Cx43 is strongly expressed [1, 2]. However, the 
levels of Cx43 protein are decreased when these cells 
acquire a malignant phenotype. In fact, the levels of 
Cx43 protein are inversely correlated with the degree 
of malignancy in astrocytomas, being negligible in the 
majority of glioblastomas, the most common glioma that 
unfortunately carries the worst prognosis [3–9]. Even in 
glioma-initiating cells or glioblastoma stem cells (GSCs)-a 
subpopulation of cells within malignant gliomas that are 
characterized by their self-renewal capacity, multilineage 
differentiation properties, high oncogenic potential, and 
resistance to standard therapies [10]- the levels of Cx43 
are negligible [11, 12]. 
The proto-oncogene tyrosine-protein kinase Src 
(c-Src) participates in signaling pathways that control 
a diverse spectrum of biological events, including 
proliferation, differentiation, survival and migration 
[13]. c-Src binds to Cx43 through the Src homology 
3 (SH3) domain binding motif of Cx43, a proline-rich 
region (amino acids 274–283), and then phosphorylates 
tyrosine 265, providing an SH2 domain binding site with 
subsequent phosphorylation at tyrosine 247 [14]. As a 
consequence of these phosphorylations, gap junctional 
intercellular communication is reduced [15–17], and 
Cx43 turnover is initiated [18]. More recently, it has been 
found that in addition to these effects, the interaction of 
Cx43 with c-Src can reciprocally inhibit c-Src activity 
[11, 19]. Glioblastoma cells exhibit strong c-Src activity 
[20], which plays an important role in the transforming 
phenotype of astrocytomas [21]. Autophosphorylation at 
tyrosine 416 activates c-Src, contributing to the malignant 
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phenotype [22]. Interestingly, restoring Cx43 to glioma 
cells reduces c-Src activity by decreasing the active form 
of c-Src (c-Src phosphorylated at tyrosine 416; Y416 
c-Src) and increasing the inactive form of c-Src (c-Src 
phosphorylated at tyrosine 527; Y527 c-Src) [19]. The 
inhibition of c-Src is not promoted by mutant Cx43, 
which lacks the ability to bind to c-Src [19]. Rather, it 
is promoted by cell-penetrating peptides containing 
the region of Cx43 involved in c-Src interaction [11]. 
Collectively, these data indicate that the interaction of 
Cx43 with c-Src reduces c-Src activity; therefore, these 
proteins are mutually regulated by a phosphorylation/
dephosphorylation loop. c-Src activity is linked to crucial 
signaling pathways [23]. Consequently, it is not surprising 
that the inhibition of c-Src promoted by Cx43 reduces the 
cell cycle [11, 19], glucose uptake [24, 25] or glioma stem 
cell phenotype [11, 19] (for a review, see [26]).
Despite the relevance of c-Src inhibition for cell 
biology, the mechanism by which the interaction of Cx43 
with c-Src reduces its activity is unknown. The inhibition 
of c-Src requires the activity of the C-terminal c-Src 
kinase (Csk), which phosphorylates c-Src at tyrosine 
527 [27]. In addition, several phosphatases, such as 
phosphatase and tensin homolog (PTEN), have been 
shown to dephosphorylate c-Src at tyrosine 416 [28], an 
activity that is required to complete the inactivation of 
c-Src. In this study, we found that a small region located 
in the C-terminal domain of Cx43 serves as a docking 
platform for c-Src, PTEN and Csk, favoring the inhibition 
of the oncogenic activity of c-Src.
rEsULts
csk and PtEN are involved in the inhibition of 
glioma cell growth promoted by cx43
In previous studies, we showed that restoring Cx43 
to glioma cells inhibits c-Src activity and consequently 
their rate of proliferation [11, 19]. Because Csk, through 
phosphorylation of c-Src at tyrosine 527, is the main 
enzyme responsible for c-Src inhibition [27], in this 
study, we addressed the participation of Csk in the 
antiproliferative effect of Cx43. To do so, the expression of 
Csk was knocked-down by a specific siRNA (Csk-siRNA) 
[29] in C6 glioma cells stably transfected with Cx43 (C6-
Cx43) or the empty vector (C6-Ires). Figure 1A shows 
that Csk-siRNA strongly reduced the expression of Csk in 
both C6-Ires and C6-Cx43 cells at concentrations ranging 
from 25 to 75 nM. Next, the growth of C6-Ires and C6-
Cx43 cells, transfected with 50 nM non-targeting siRNA 
(NT-siRNA), or Csk-siRNA, was followed using the 
MTT assay. Figure 1B shows that, as expected, restoring 
Cx43 reduced the rate of glioma cell growth in the control 
situation (cells transfected with NT-siRNA). However, 
when Csk was silenced the effect of Cx43 on glioma cell 
proliferation was reduced, suggesting the contribution of 
Csk to the antiproliferative effect of Cx43. It should be 
mentioned that the growth rate increased when Csk was 
silenced in both C6-Ires (p < 0.01 at days 3 and 4, and 
p < 0.001 for the other days) and C6-Cx43 (p < 0.05 at day 
3 and p < 0.001, for the other days) cells compared with 
cells transfected with NT-siRNA. 
In addition to the phosphorylation at tyrosine 527 
by Csk, to be completely inactivated, c-Src needs to be 
dephosphorylated at tyrosine 416. Several phosphatases, 
including PTEN, have been shown to dephosphorylate 
c-Src at tyrosine 416 [28]. To investigate the participation 
of PTEN in the inhibition of c-Src promoted by Cx43 
[19], the levels of Y416 c-Src were analyzed in glioma 
cells in which PTEN was knocked-down by siRNA [30] 
(Figure 1C–1E). As expected, Cx43 decreased the ratio 
of Y416 c-Src / total c-Src in glioma cells transfected 
with NT-siRNA (Figure 1E). By contrast, when PTEN 
was silenced by a specific siRNA (PTEN-siRNA), Cx43 
could not reduce this ratio (Figure 1E), suggesting that 
PTEN is involved in the dephosphorylation of c-Src at 
tyrosine 416. Next, we investigated the participation of 
PTEN in the antiproliferative effect of Cx43. Our results 
showed that silencing PTEN reduced the antiproliferative 
effect of Cx43 on glioma cells compared with glioma 
cells transfected with NT-siRNA (Figure 1B). The growth 
rate increased when PTEN was silenced in both C6-Ires 
(p < 0.01 at days 3 and 7, and p < 0.001 for the other days) 
and C6-Cx43 (p < 0.01 at days 3 and 7, and p < 0.001 for 
the other days) cells compared with cells transfected with 
NT-siRNA. 
restoring cx43 expression in glioma cells 
increases PtEN by a c-src-dependent 
mechanism
Unexpectedly, we observed that the presence of 
Cx43 increased PTEN protein levels in glioma cells 
(Figure 1C). Because PTEN is one of the most relevant 
tumor suppressor proteins in gliomas [31], we decided 
to explore this effect. To this end, the levels of PTEN 
were analyzed in C6-Ires and C6-Cx43 cells. Our results 
showed that restoring Cx43 expression doubled the levels 
of PTEN protein in glioma cells (Figure 2A and 2C).
To confirm the functionality of PTEN, we analyzed 
its downstream pathway. PTEN exhibits both lipid and 
protein phosphatase activities. The main substrate for 
the lipid phosphatase activity is phosphatidylinositol-
trisphosphate (PIP3), which is dephosphorylated by 
PTEN to generate PIP2. PIP3 is the main activator 
of Akt [32]. Thus, the higher the activity of PTEN, 
the lower the activity of Akt. In agreement with this 
concept, restoring Cx43 expression reduced Akt activity 
as shown by the concomitant reduction in the levels of 
Akt phosphorylated at serine 473 and threonine 308 
(Figure 2A, 2G and 2H) and the increase in PTEN levels 
(Figure 2A and 2C). 
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Figure 1: Effect of silencing csk and PtEN on the reduction of proliferation promoted by cx43. C6 cells stably transfected 
with the empty vector (C6-Ires) or the vector containing the Cx43 cDNA (C6-Cx43) were transfected with Csk-siRNA, PTEN-siRNA 
or non-targeting siRNA (NT-siRNA). (A) The levels of Csk were analyzed by Western blotting 72 h after transfection with increasing 
concentrations of Csk-siRNA or 50 nM NT-siRNA. The results are the means ± s.e.m. (n = 3) and they are expressed as the percentage of 
the corresponding NT-siRNA. ***p < 0.001 versus the corresponding NT-siRNA. (b) The cells transfected with the indicated siRNAs were 
plated at 2000 cells/cm2, and the number of living cells was followed by the MTT assay. The results are the means ± s.e.m. (n = 4) and they 
are expressed as the absorbance values of the MTT assay. *p < 0.05, **p < 0.01, ***p < 0.001; C6-Ires versus C6-Cx43. (c) Cells were 
transfected with 50 nM NT-siRNA or PTEN-siRNA. After 48 h, PTEN, Cx43, total c-Src and Y416 c-Src levels were analyzed by Western 
blotting. The results are the means ± s.e.m. (n = 6) and they are expressed as the percentage of the C6-Cx43 NT-siRNA (D) or as the ratio 
of Y416 c-Src/total c-Src (E). n.s: not significant. **p < 0.01 and ***p < 0.001.
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Figure 2: Effect of cx43 and mutant cx43 expression on PtEN expression and Akt activity. C6 glioma cells were stably 
transfected with the empty vector (C6-Ires), the vector containing the Cx43 cDNA (C6-Cx43), or the vector containing the cDNA encoding 
the double mutant Cx43 in which tyrosine 247 and tyrosine 265 of Cx43 were replaced by non-phosphorylatable phenylalanines (C6-Cx43 
Y247F/Y265F). Western blots (A) and quantification of Cx43 (b), PTEN (c), total c-Src (D), Y416 c-Src (E), total Akt (F), S473 Akt (G) 
and T308 Akt (H). The results are the means ± s.e.m. (n = 6) and they are expressed as percentage of the value generated by C6-Ires cells. 
*p < 0.05, **p < 0.01, ***p < 0.001 versus C6-Ires.
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Because the activity of c-Src promotes PTEN 
degradation and reduces its ability to inhibit the PI3K/Akt 
pathway [33], we analyzed the involvement of c-Src in the 
effect of Cx43 on PTEN. C6 cells were stably transfected 
with a double Cx43 mutant in which tyrosines 247 and 265 
were replaced with non-phosphorylatable phenylalanines 
(C6-Cx43Y247F/Y265F). This mutant lacks the ability to 
bind to c-Src [15, 17] and, consequently, does not inhibit 
c-Src activity like wild-type Cx43 [19] (Figure 2A, 2D 
and 2E). Our results showed that the mutant Cx43 did not 
significantly modify the levels of PTEN (Figure 2A and 2C), 
suggesting that the Cx43-mediated inactivation of c-Src is 
required to increase the levels of PTEN. In agreement with 
the lack of effect on PTEN levels, mutant Cx43 did not 
significantly modify the levels of active Akt phosphorylated 
at serine 473 and threonine 308 (Figure 2A, 2G and 2H).
cx43 binds to PtEN and csk
The ability of Cx43 to bind to c-Src has been well 
described [15, 17, 34]. Because our results suggested 
that Csk and PTEN participate in the inhibition of c-Src 
activity promoted by Cx43, we postulated that Cx43 could 
recruit these enzymes to achieve the inactivation of c-Src. 
To test this hypothesis, glioma cells were transfected with 
HA-PTEN or the empty vector (pSG5L). After 24 h, HA 
was immunoprecipitated (Figure 3A). Our results showed 
that the antibody against HA precipitated HA-PTEN, 
Cx43, c-Src and Csk in glioma cells transfected with 
Cx43 but not in glioma cells that lacked Cx43 expression 
(C6-Ires) or in C6-Cx43 cells transfected with pSG5L, 
suggesting that restoring Cx43 to glioma cells promotes 
its binding to PTEN, c-Src and Csk in glioma cells. 
To address whether this interaction occurs between 
endogenously expressed proteins, astrocytes, which 
naturally express high levels of Cx43 and PTEN, were 
analyzed. Thus, Cx43 was immunoprecipitated, and the 
presence of PTEN was identified in the immunocomplex 
of Cx43 (Figure 3B). Reciprocally, Cx43 was also 
found after immunoprecipitation with antibodies against 
Csk in astrocytes. No signals were observed after the 
immunoprecipitation without IgG (data not shown) or with 
non-relevant IgGs, such as a mouse monoclonal antibody 
against hexokinase-1 (Hx-1) or glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) used as negative controls.
To confirm the results of immunoprecipitation, 
immunofluorescence analyses were carried out for Cx43, 
PTEN and Csk in astrocytes. The distribution of these 
proteins (Figure 3C; Cx43 in red and PTEN or Csk in 
green) was analyzed using a confocal microscope. The 
yellow color in the overlay images confirmed certain 
areas of colocalization between Cx43 and PTEN or Csk in 
astrocytes (Figure 3C). This colocalization can be visualized 
in the Z-projection of the stack images (Figure 3C). In 
addition, C6 glioma cells were transiently transfected with 
Cx43, and PTEN (green) and Cx43 (red) were analyzed 
by immunofluorescence 48h later. The confocal images 
showed some points of colocalization (yellow) between the 
two proteins in the overlay image (Figure 3D). 
region of cx43 involved in the PtEN and csk 
binding
Regarding the molecular bases underlying the Cx43-
PTEN binding, both Cx43 and PTEN harbor a functional 
PDZ domain-binding motif (residues 380–382 in Cx43 [35] 
and residues 401–403 in PTEN [36]) at their C-terminal 
tail. Therefore, we hypothesized that Cx43 and PTEN could 
interact through a scaffolding protein containing several 
PDZ domains. For instance, Zonula occludens-1 (ZO-1) 
binds to Cx43 through one of its three PDZ domains [35]; 
therefore, although a direct interaction between ZO-1 and 
PTEN has not been reported, it might occur in one of the 
remaining PDZ domains in ZO-1. To test this concept, C6-
Cx43 glioma cells or astrocytes were transfected with a 
mutant PTEN that lacks the PDZ domain-binding motif 
(residues 1–400; Flag ΔPDZ-PTEN), wild-type PTEN 
(Flag WT-PTEN) or the empty vector (Flag) (Figure 4). 
Flag immunoprecipitation revealed that the mutant PTEN 
retains the ability to bind to Cx43 and c-Src in glioma 
cells (Figure 4A) and to Cx43, c-Src and Csk in astrocytes 
(Figure 4B), indicating that the PDZ domain-binding motif 
is not required for these interactions. 
Our previous results suggested that cell-penetrating 
peptides (CPPs) containing Cx43 residues involved in the 
c-Src interaction (residues 245–283 and 266–283 but not 
274–283 in the C-terminal domain of Cx43 (Cx43CT)) 
inhibit the activity of c-Src [11]. Therefore, we investigated 
whether these peptides could recruit the machinery 
required to inhibit c-Src activity. To address this point, 
C6 glioma cells were incubated with biotinylated CPPs 
containing the SH3 domain binding motif and tyrosines 
phosphorylated by c-Src (from amino acid 245 to 283), 
the same sequence excluding the tyrosines (from amino 
acid 266 to 283) or a consensus SH3 domain binding 
motif (from amino acid 274 to 283) (Figure 5A). These 
peptides were all fused to the TAT penetrating sequence 
(YGRKKRRQRRR). After 30 minutes, pull-down assays 
were performed, the biotinylated peptides were recovered 
and proteins bound to them were analyzed (Figure 5B). 
Our results showed that as expected [37], c-Src was found 
in complex with TAT-Cx43-266-283-B, TAT-Cx43-245-
283-B and, to a lesser extent, TAT-Cx43-274-283-B. 
Interestingly, PTEN and Csk were mainly bound to TAT-
Cx43-266-283-B and, to a lesser extent, TAT-Cx43-245-
283-B, suggesting that this region of Cx43 (266–283) 
recruits not only c-Src but also PTEN and Csk. These 
proteins were not found when the cells were incubated with 
TAT-B, confirming that the sequence of Cx43 containing 
the residues 266–283 is sufficient to recruit c-Src, PTEN 
and Csk. The cellular internalization of these peptides was 
confirmed by fluorescence microscopy (Figure 5C).
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Figure 3: Interaction between cx43, c-src, csk and PtEN in c6 glioma cells and astrocytes. (A) C6 glioma cells stably 
transfected with the empty vector (C6-Ires) or the vector containing the Cx43 cDNA (C6-Cx43) were transfected with HA-PTEN or pSG5L 
(empty vector). After 24 h, the cells were lysed and immunoprecipitated with anti-HA antibodies. Western blotting before (lysates) and after 
HA immunoprecipitation for PTEN, Cx43, c-Src and Csk showing the presence of Csk, c-Src and Cx43 in the immunocomplex obtained 
with HA-PTEN in glioma cells expressing Cx43. (b) Astrocytes from primary culture were lysed and immunoprecipitated with antibodies 
against Cx43 or Csk. Antibodies against hexokinase-1 (Hx-1) and GAPDH were used as controls. (c) Colocalization of Cx43 with Csk 
and PTEN in astrocytes. Confocal images show Cx43 (red) and Csk or PTEN (green) and their colocalization (yellow). Scale bars: 15 μm. 
Orthogonal projections along the z-axis of the images are shown at the bottom and right. (D) Colocalization of PTEN and Cx43 in C6 
glioma cells transiently transfected with the construct containing Cx43 cDNA. The confocal images show PTEN (green), Cx43 (red) and 
overlay image with some points of colocalization (yellow). Note that only one Cx43-transfected cell is shown. Scale bar: 10 μm.
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tAt-cx43-266-283 inhibits human glioblastoma 
stem cell growth in a PtEN-dependent fashion
To confirm that the recruitment of PTEN and Csk 
to the sequence of Cx43 containing residues 266–283 is 
sufficient to inhibit c-Src and its downstream pathway, 
we tested the effect of the peptide TAT-Cx43-266-283 on 
G166 human glioblastoma stem cells (GSCs) [38]. 
Our results showed that TAT-Cx43-266-283 reduced 
c-Src activity as evidenced by decreased levels of Y416 
c-Src, increased PTEN protein levels and subsequently 
reduced Akt activity (T308 Akt) (Figure 6A). 
As a consequence of the inhibition of these 
proliferative pathways, TAT-Cx43-266-283 reduced 
GSC proliferation compared with the control or TAT 
peptides (Figure 6B–6D and Supplementary Figure S1). 
Interestingly, when PTEN was knocked-down by 
siRNA (Figure 6E), TAT-Cx43-266-283 was not able to 
significantly affect GSC growth. This result was in contrast 
to the observations made in GSCs transfected with a NT-
siRNA (Figure 6F) and confirms the participation of PTEN 
in the inhibition of c-Src that is promoted by the sequence 
of Cx43 containing the residues 266–283.
DIscUssION
High-grade glioma cells exhibit reduced levels 
of Cx43 protein [3–9] but increased c-Src activity [20]. 
Importantly, restoring Cx43 expression inhibits the activity 
of c-Src [11, 19], reduces glioma cell proliferation [39, 40] 
and reverses glioma stem cell phenotype [11, 12]. In this 
study, we revealed the mechanism by which Cx43 inhibits 
the oncogenic activity of c-Src. Our results showed that 
Cx43, in addition to c-Src, recruits Csk and PTEN, which 
are the enzymes required to inhibit c-Src activity. 
The Csk-mediated phosphorylation of c-Src at 
tyrosine 527 is the best-described mechanism for c-Src 
inactivation [41]. The completion of this inhibition 
requires the dephosphorylation of c-Src at tyrosine 416 
[42]. Our results suggest that in C6 glioma cells, as in 
other cell types [28, 43], PTEN is the phosphatase that 
catalyzes this process. Indeed, silencing PTEN prevented 
the reduction of Y416 c-Src that was promoted by Cx43 
in glioma cells. In addition, when either Csk or PTEN 
was silenced and c-Src activity could not be inhibited, 
the antiproliferative effect of Cx43 on glioma cells 
was reduced. It can be concluded that Csk and PTEN 
participate in the antiproliferative effect of Cx43 by 
inhibiting c-Src. 
Intriguingly, our results showed that restoring Cx43 
expression in glioma cells up-regulates the levels of 
functionally active PTEN protein. Indeed, PI3K/Akt, the 
main PTEN downstream pathway, is subsequently inhibited. 
Because the mutant Cx43 that lacks the ability to inhibit 
c-Src activity [19] did not modify PTEN levels or activity, 
it could be proposed that the effect of Cx43 on PTEN levels 
is a consequence of c-Src inhibition. In agreement with this 
proposal, the activity of c-Src promotes PTEN degradation 
and the subsequent activation of the PI3K/Akt pathway 
[33]. By showing that Cx43 up-regulates PTEN, one of the 
Figure 4: PtEN PDZ domain-binding motif is not required for PtEN interaction with cx43, c-src, and csk. C6-Cx43 
cells (A) or astrocytes (b) were transfected with Flag WT-PTEN, Flag ΔPDZ-PTEN (1-400; PTEN lacking the PDZ domain-binding motif) 
or Flag (control). After 48 h, the cells were lysed, and immunoprecipitations were carried out with antibodies against Flag. Western blotting 
before (lysates) and after Flag immunoprecipitation for Flag, Cx43, c-Src, PTEN and Csk showing the presence of c-Src and Cx43 in the 
immunocomplex obtained with both WT-PTEN and ΔPDZ-PTEN in glioma cells expressing Cx43 and the presence of c-Src, Csk and Cx43 
in the immunocomplex obtained with both WT-PTEN and ΔPDZ-PTEN in astrocytes that endogenously express Cx43.
Oncotarget49826www.impactjournals.com/oncotarget
Figure 5: the cx43 region involved in the recruitment of PtEN and csk. C6 glioma cells were incubated with several cell-
penetrating peptides containing the indicated sequences of Cx43 fused to biotin for 30 min. (A) The SH3 domain binding motif is shown 
in grey and the tyrosines phosphorylated by c-Src in red. (b) After 30 min, the cells were lysed, and pull-down assays were carried out 
with avidin-conjugated agarose beads. Western blots before (lysates) and after avidin pull-down for c-Src, Csk and PTEN showing the 
enrichment of PTEN and Csk in the complex obtained with TAT-Cx43-266-283-Biotin and, to a lesser extent, with TAT-Cx43-245-283-
Biotin. Str-HRP, HRP-conjugated streptavidin. (c) After 30 min, the cells were fixed, and the uptake of peptides bound to biotin was 
analyzed by fluorescence microscopy. Scale bars: 15 μm.
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Figure 6: Involvement of PtEN in the antiproliferative effect of tAt-cx43-266-283 on G166 human glioblastoma stem 
cells. G166 cells were incubated with 50 µM TAT or TAT-Cx43-266-283 for the indicated times. (A) After 48 h, total c-Src, Y416 c-Src, 
PTEN, total Akt and T308 Akt levels were analyzed by Western blotting. (b) The cells were plated at a density of 5000 cells/cm2 and the 
number of living cells was monitored over a 3 day period by the MTT assay. Means ± s.e.m. (n = 3). (c) Representative phase-contrast 
images showing the inhibition of proliferation promoted by TAT-Cx43-266-283. Scale bars: 50 μm. (D) Percentage of Ki-67-positive 
cells found after 48h. Means ± s.e.m (n = 3). ** p < 0.01 versus control. (E) G166 cells were plated at 7500 cells/cm2 and transfected with 
PTEN-siRNA or non-targeting siRNA (NT-siRNA). After 48 h, PTEN levels were analyzed by Western blotting. (F) G166 cells were 
plated at 7500 cells/cm2 and transfected with 150 nM NT-siRNA or PTEN-siRNA. After 24 h, the cells were incubated with 50 µM TAT 
or TAT-Cx43-266-283 for 48 h and the number of living cells was analyzed by the MTT assay. Means ± s.e.m. (n = 3). **p < 0.01 versus 
TAT NT-siRNA.
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most relevant tumor suppressor genes in gliomas [44, 45], 
and inhibits PI3K/Akt, an important proliferative pathway 
that is frequently up-regulated in glioma [46], these results 
expand our knowledge of the mechanism by which Cx43 
suppresses tumor growth (Figure 7). 
This study shows that in astrocytes, that express high 
levels of endogenous Cx43, there is also an interaction 
between Cx43, c-Src, Csk and PTEN, indicating that the 
regulation of c-Src activity is a physiological function of 
Cx43. c-Src phosphorylates tyrosines 265 and 247 [14], 
which strongly affects Cx43 structure and function [26, 37] 
and the interaction of Cx43 with several partners [47–49]. 
To terminate these effects, the phosphatase TC- PTP is 
recruited to remove the phosphates at tyrosines 265 and 
247 of Cx43 [50]. However, if c-Src remained active, 
it would continue to phosphorylate Cx43. Our results 
suggest that Cx43 phosphorylation by c-Src could also be 
a signal to recruit PTEN and Csk to this complex. The 
inhibition of c-Src activity promoted by PTEN and Csk 
would collaborate with TC-PTP to terminate this pathway, 
which is required to recycle Cx43 [51]. In this way, the 
transient and dynamic interactions of these proteins would 
contribute to the maintenance of the homeostasis of the 
gap junction channel and hemichannel activities.
Although both PTEN and Cx43 contain PDZ-
binding motifs, our results indicated that these regions 
Figure 7: Proposed mechanism by which cx43 inhibits the activity of c-src. Our results showed that the region of Cx43 that 
comprises amino acids 266-283 (in red), located in one of the intrinsically disordered regions of Cx43CT, serves as a docking platform for 
the active form of c-Src (c-Src phosphorylated at tyrosine 416, shown in yellow), Csk and PTEN. The proximity of these proteins facilitates 
the phosphorylation of c-Src at tyrosine 527 (green) catalyzed by Csk and the removal of phosphate at tyrosine 416 (yellow) catalyzed by 
PTEN with the subsequent inhibition of c-Src activity. c-Src inhibition prevents PTEN degradation creating a positive feed-forward loop 
to guarantee the long-term regulation of this process. As a consequence of increased PTEN, Akt activity decreases. This signaling pathway 
contributes to a reduction in the oncogenic activity of these proteins in glioma cells.  
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are not required for the interaction between these 
proteins. Instead, the region of Cx43 that is involved in 
its interaction with c-Src (residues 266–283) is sufficient 
to recruit PTEN and Csk. In agreement with this finding, 
CPPs containing this sequence (TAT-Cx43-266-283) 
inhibited the oncogenic activity of c-Src [11], increased 
PTEN, reduced Akt activity and subsequently decreased 
human glioblastoma stem cell proliferation. 
Since it was first described, the relationship 
between Cx43 and cancer has been deeply investigated 
[52]. However, it should be noted that although restoring 
Cx43 expression in glioma cells reduces proliferation, 
it can also have detrimental effects due to gap junctional 
communication or cytoskeletal interactions [53–56]. There 
is interest in the short sequence (residues 266–283) of Cx43 
because it inhibits the oncogenic activity of c-Src and lacks 
the ability to interact with the cytoskeleton or to form gap 
junction channels. Nevertheless, unexpected effects cannot 
be ruled out. Therefore, further studies should be carried out 
to explore the therapeutic potential of this sequence in depth. 
In conclusion, we propose that the Cx43-mediated 
inhibition of c-Src involves the recruitment of the c-Src 
inhibitors Csk and PTEN to residues 266–283 within 
Cx43CT. Furthermore, upon c-Src inhibition, Cx43 up-
regulates PTEN and subsequently inactivates Akt to 
sustain its tumor suppressor properties (Figure 7). These 
results stress the relevance of Cx43 residues 266–283 for 
the development of new therapies to reduce the oncogenic 
activity of c-Src. In contrast to the available c-Src 
inhibitors, this approach uses an endogenous inhibitory 
mechanism, making off-target effects less likely.
MAtErIALs AND MEtHODs
cell cultures
Astrocytes in primary culture were prepared from 
the forebrains of 1- to 2-day-old Wistar rats and cultured 
in DMEM (Sigma-Aldrich Química, Madrid, Spain) 
supplemented with 10% FCS (Gibco, Life Technologies, 
Madrid, Spain), as previously described [57]. C6 glioma 
cells (ATCC, Manassas, USA) were cultured in DMEM 
supplemented with 10% FCS as previously described [19]. 
The G166 human GSC line was obtained from BioRep 
(Milan, Italy). The cells were grown in petri dishes coated 
with 10 mg/ml laminin (Life Technologies). The growth 
medium was RHB-A (StemCells, Cambridge, UK) 
supplemented with 1% N2, 2% B27 (Life Technologies), 
20 ng/ml EGF and 20 ng/ml b-FGF (PeproTech, London, 
UK) as described previously [11].
Plasmid constructs and cell transfection
The pIRES-Cx43 construct was generated as 
previously reported [19] by ligating a PCR-amplified 
fragment encoding the rat Cx43 sequence (NM_012567) 
into the XhoI-BamHI sites of the bicistronic pIRES2-
DsRed2 vector (Clontech, Palo Alto, CA, USA). The 
Cx43Y247F/Y265F mutation was introduced into pIRES-
Cx43 by site-directed mutagenesis [19]. C6-Ires, C6-Cx43 
and C6-Cx43 Y247F/Y265F clones were generated and 
characterized as previously described [19]. Unless otherwise 
specified, the C6 glioma cells were stably transfected with 
the empty vector (C6-Ires), the construct containing Cx43 
(C6-Cx43) or the construct containing the mutant Cx43 
(C6-Cx43Y247F/Y265F) using Lipofectamine 2000 (Life 
Technologies). For stable transfection cells were selected 
with 0.5 mg/ml G418 (Promega, Madison, WI, USA) in 
DMEM supplemented with 10% (v/v) FCS. 
The pSG5L, pSG5L HA-PTEN, pCMV FLAG WT-
PTEN and pCMV FLAG ΔPDZ-PTEN (1–400) plasmids 
were a gift from William Sellers and Hong Wu and were 
obtained from Addgene (Addgene plasmid 10737, 10750, 
22231 and 22232, respectively) [58, 59]. Cells were 
transiently transfected using Lipofectamine 2000, as 
described above. 
transfection of sirNA
C6-Cx43 clone 7 cells were transfected with a 
validated non-targeting siRNA (NT-siRNA), a siRNA 
specific for Csk (Csk-siRNA) or a siRNA specific 
for PTEN (PTEN-siRNA) (BioNova Científica S.L., 
Madrid, Spain). Cells were transfected with the double-
strand siRNA complexed with 3 μl/ml Lipofectamine 
2000 (Life Technologies) in culture medium without 
antibiotics. The cells were maintained in the presence of 
the oligonucleotides in culture medium without antibiotics 
for 6 h. The extent of siRNA-mediated down-regulation 
of Csk or PTEN expression was evaluated by Western 
blot analysis. The Csk-siRNA sequences were as follows: 
sense 5′-AGUACCCAGCAAAUGGGCATT-3′ and 
antisense 5′-UGCCCAUUUGCUGGGUACUTT-3′ [29]. 
The PTEN-siRNA sequences were as follows: sense 
5′-GUUAGCAGAAACAAAAGGAGATT-3′ and antisense 
5′-UCUCCUUUUGUUUCUGCUAACTT-3′ [30].
Peptide treatments
The synthetic peptides (> 90% pure) were 
obtained from GenScript (Piscataway, NJ, USA). 
All peptides used were biotinylated via a C-terminal 
lysine. YGRKKRRQRRR-Lys(biotin) was used as the 
TAT sequence (TAT-B), which is responsible for cell 
penetration of the peptides [60]. The sequence for TAT-
Cx43-245-283-B was YGRKKRRQRRRDPYHATSGAL
SPAKDCGSQKYAYFNGCSSPTAPLSPMSP-Lys(biotin), 
the sequence for TAT-Cx43-266-283-B was YGRKKRRQ 
RRRAYFNGCSSPTAPLSPMSP-Lys(biotin) and  the 
sequence for TAT-274-283-B was YGRKKRRQRRR 
PTAPLSPMSP-Lys(biotin). Peptides were used at 50 μM 
in culture medium at 37 °C for the indicated times.
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Mtt assay
Cells cultured at 37°C in 24-well-plates were 
incubated in the dark for 75 min with 300 μl of DMEM 
containing 0.5 mg/ml MTT. The medium was then 
removed, and the cells were incubated for 10 min in the 
dark with dimethyl sulfoxide (500 μl/well). Finally, the 
absorbance was measured at a wavelength of 570 nm 
using a microplate reader (Appliskan 2001; Thermo 
Electron Corporation, Waltham, MA, USA).
Western blot analysis 
Western blotting was performed as previously 
described [11]. Briefly, equivalent amounts of proteins 
(20 μg per lane) were separated on NuPAGE Novex Bis-
Tris (4–12% or 10%) midigels (Life Technologies). Proteins 
were transblotted using an iBlot dry blotting system (Life 
Technologies). The membranes were cut into several strips 
to be immunoblotted with distinct antibodies, thus allowing 
for comparative analysis of the amount of each protein in 
the same sample. Membranes were then blocked for 1 h 
at room temperature in Tris-buffered saline containing 
0.05% Tween 20 (TTBS) and 7% non-fat milk powder 
before being incubated overnight at 4 °C with the primary 
antibodies. The primary antibodies used were: Cx43 (1:250; 
BD Biosciences, Madrid, Spain; Ref. 610062); total c-Src 
(1:500; Ref. 2108); Y416 c-Src (1:250; Ref. 2101), Y527 
c-Src (1:500; Ref. 2105), Csk (1:500; Ref. 4980), PTEN 
(1:500; Ref. 9552), total Akt (1:1000; Ref. 9272), S473 Akt 
(1:2000; Ref. 4060), T308 Akt (1:1000; Ref. 4056) (all from 
Cell Signaling, Danvers, MA, USA), GAPDH (1:6000; 
Ambion; Ref. AM4300) or α -actinin (1:1000; Merck 
Millipore, Darmstadt, Germany; Ref. MAB1682). After 
extensive washing, the membranes were incubated with 
HRP-conjugated antibodies (Santa Cruz Biotechnology, Inc., 
Dallas, TX, USA; Refs. sc-2030 and sc-2005) in TTBS. The 
proteins were developed with a chemiluminescent substrate. 
Densitometry analysis of the bands was performed using the 
Image J program (Wayne Rasband; NIH, Bethesda, MD, 
USA). The amounts of GAPDH or α-actinin recovered in 
each sample served as the loading control, and the values 
for each protein were normalized to their corresponding 
GAPDH or α-actinin level.
Immunofluorescence 
Immunofluorescence was performed as previously 
described [11]. The cells were incubated overnight at 
4ºC with primary antibodies against Cx43 (1:100; BD 
Biosciences; Ref. 610062), Csk (1:100), and PTEN 
(1:100) (both from Cell Signaling; Refs. 4980 and 9552). 
The secondary antibodies used were as follows: Cy5 goat 
anti-mouse (1:500; Jackson ImmunoResearch, Baltimore, 
PA, USA; Ref. 115-175-003) and Alexa Fluor 488 goat 
anti-rabbit (1:1000; Life Technologies, Ref. A-11029). The 
cells were mounted using the SlowFade Gold Antifade kit 
(Life Technologies) and were analyzed using a Leica DM-
IRE2 confocal microscope and LCS Lite software (Leica 
Microsystems, Wetzlar, Germany). 
co-immunoprecipitation 
Twenty-one DIV astrocytes or C6 cells grown to 
confluence in 10-cm dishes were washed with ice-cold 
PBS and lysed at 4°C in 1 ml of SDS-free RIPA buffer 
(10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.2% Triton 
X-100, 2 mM EDTA, 2 mM EGTA, 1 mM PMSF, 1:100 
(v/v) protease cocktail (Cocktail III; Calbiochem Merck-
Millipore, Billerica, MA, EE.UU), 1 mM NaF and 0.1 
mM Na3VO4). Lysates were centrifuged at 11000 × g 
for 10 min at 4°C, and the supernatants were recovered. 
A 25-µl aliquot was used to analyze the protein content 
(lysates), and the remaining lysate (immunoprecipitation) 
was incubated with 2 µg of mouse monoclonal antibody 
against hexokinase I (Merck Millipore; Ref. MAB1532), 
mouse monoclonal antibody against HA (Roche, Basel, 
Switzerland Ref.11 583 816 001), mouse monoclonal 
antibody against Cx43 (BD Biosciences; Ref. 610062), 
rabbit monoclonal antibody against Csk (Cell Signaling; 
Ref. 4980) or rabbit monoclonal antibody against 
GAPDH (Ambion; Ref. AM4300) for 12 h at 4°C with 
gentle shaking. The immunocomplexes were sequestered 
by adding 50 μl of Protein-A Sepharose CL-4B (GE 
Healthcare, Madrid, Spain), which was previously saturated 
with 5% (w/v) albumin and gently shaken at 4°C for 4 h. 
The Protein-A beads containing the immunocomplexes 
were collected by centrifugation (11000 × g for 1 min at 
4°C). The beads were then washed four times with buffer 
A (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, Triton X-100 
and 2 mM EDTA), once with buffer B (10 mM Tris-HCl 
(pH 8.0), 500 mM NaCl, 0.2% Triton X-100 and 2 mM 
EDTA) and once with buffer C (10 mM Tris-HCl (pH 8.0)). 
The bound proteins were eluted with SDS sample buffer at 
95°C for 5 min. After centrifugation, the supernatants were 
analyzed by Western blotting.
For Flag fusion proteins, the lysis buffer contained 
20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 1% IGEPAL 
(p/v), 1 mM PMSF, 1:100 (v/v) protease cocktail (Cocktail 
III, Calbiochem), 1 mM NaF and 0.1 mM Na3VO4. The 
lysates were incubated with anti-Flag M2 Affinity Gel 
(40 µl per ml; Sigma, Saint Louis, MO, USA; Ref.F7425) 
for 12 h at 4°C with gentle shaking. The anti-Flag beads 
containing the immunocomplexes were collected by 
centrifugation (11000 × g for 1 min at 4°C) and washed 
five times with lysis buffer, and the bound proteins were 
eluted and analyzed by Western blotting.
Avidin pull-down assay
Cells grown in 3.5-cm dishes were incubated with 
50 µM biotinylated peptides for 30 min. Proteins were 
then collected in 1 ml of lysis buffer (20 mM Tris-HCl (pH 
8.0), 137 mM NaCl, 1% IGEPAL, 1 mM PMSF, protease 
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cocktail (1:100; Cocktail III, Calbiochem), 1 mM NaF and 
0.1 mM Na3VO4). Lysates were centrifuged at 11000 × g 
for 10 min at 4°C, and the supernatants were recovered. 
A 25-µl aliquot of each lysate was used to analyze the 
protein content, and the remaining lysate was incubated 
with NeutrAvidin-Agarose (Thermo Scientific, Rockford, 
IL, USA; Ref. 29200) for 12 h at 4°C with gentle shaking. 
The avidin beads bound with the peptides were collected 
by centrifugation (3000 × g for 1 min at 4°C). The beads 
were then washed five times with lysis buffer, and the 
bound proteins were eluted and analyzed by Western 
blotting. To detect biotinylated peptides, the membranes 
were incubated with HRP-conjugated streptavidin in 
TTBS (1:40000, Ref. 434323, Life Technologies) and then 
developed with a chemiluminescent substrate.
In parallel, the cells were incubated with 50 µM 
biotinylated peptides for 30 min. The cells were 
then washed with PBS at 4ºC and fixed with 4% 
paraformaldehyde for 20 min. After washing, the cells 
were incubated with Cy2-conjugated streptavidin (1:500; 
Jackson ImmunoResearch, Baltimore, USA; Ref. 016-
220-084) for 1 h, mounted and visualized as described 
previously.
statistical analyses
The results were expressed as the means ± s.e.m. of 
at least three independent experiments. Statistical analyses 
were carried out using Student’s t-test when two groups 
were compared. For the comparison of more than one group, 
analysis of variance (one-way ANOVA) was used, followed 
by an appropriate post -test (Dunnet or Tukey). Values were 
considered significant with a p value less than 0.05.
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